-
US equities open in the red as trade pessimism persists
-
Treasuries sink following lower than expected inflation data
-
Boeing’s shares sell off on deadly plane crash in India
Wall Street continues to post moderate declines amid ongoing trade tensions, as the deadline for post–Liberation Day negotiations approaches, falling short of the earlier promise of “90 deals in 90 days.”
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appInvestor sentiment remains cautious, with key agreements involving China and the European Union now expected to stretch well beyond July 1st. The uncertainty has been further amplified by President Trump's suggestion of potential new unilateral tariffs in the coming weeks. Among the major indices, the Russell 2000 leads the losses (-0.75%), followed by the Dow Jones Industrial Average (-0.4%), the Nasdaq (-0.2%), and the S&P 500 (-0.15%).
The lower-than-expected PPI has once again heightened market expectations for rate cuts in the U.S., as reflected by another decline in Treasury yields—10-year notes have slipped to 4.37% from 4.5% yesterday. However, the figures remain higher than the previous month's, indicating subdued yet persistent inflation dynamics, which continue to support the Fed’s current pause.
US100 (H1)
The US100 has recovered some of yesterday’s losses caused by a rise in CPI inflation. Today's lower-than-expected PPI inflation data has added bullish momentum, although the index still has a long way to go before coming back to the green. The index is currently trading within a channel between 21,973 and 21,470, which represent key resistance and support levels, respectively. A breakout beyond either of these levels could signal the emergence of a clearer trend for the US100. A more definitive outcome in U.S.–China negotiations will be crucial for the direction of the American index.
Source: xStation5
Company news
-
BioNTech will acquire CureVac in a $1.25 billion all-stock deal to strengthen its cancer pipeline, offering a 34% premium to CureVac shareholders. The deal unites former Covid vaccine rivals, with CureVac pivoting to oncology after its shot failed. CureVac shares jumped 37% at the opening. The German government will exit its 13.3% stake, and the deal has backing from key CureVac investors.
-
Boeing shares slumped 4.5% after an Air India 787 Dreamliner crashed shortly after takeoff from Ahmedabad en route to London, killing all 242 on board. The crash, involving the US planemaker’s most advanced widebody, is the worst since MH17 in 2014. The incident adds to Boeing’s mounting safety woes. Air India, amid a major fleet overhaul, faces scrutiny as the tragedy occurred in a residential area, prompting flight suspensions at Ahmedabad airport and emergency response coordination by Indian authorities.
-
GameStop shares fell 19% after announcing a $1.75 billion zero-coupon convertible bond offering, one of 2025’s largest equity-linked deals. Proceeds may fund acquisitions and Bitcoin investments under a revised policy. This follows a $1.5 billion March bond sale aimed at crypto exposure, echoing Michael Saylor’s strategy. The new 2032 bonds include a 35–40% conversion premium. If completed, GameStop would top this year’s equity-linked issuance rankings. Pricing is expected post-market, with TD Securities managing the deal.
-
Oracle shares surged over 11% after delivering strong Q1 2025 results, beating revenue and EPS estimates. Cloud services and license support revenue rose 14% YoY, with total cloud revenue hitting $6.7B. Boosted by major AI clients like OpenAI, Meta, and a massive new deal with Temu, Oracle is cementing its role in high-performance cloud infrastructure. With shares nearing all-time highs, upbeat forecasts and aggressive expansion signal strong momentum in its bid to rival AWS, Azure, and Google Cloud.
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.